Press Release: Sanofi successfully priced an inaugural
sustainability-linked bond indexed on access to medicines
Sanofi successfully priced an inaugural
sustainability-linked bond indexed on access to medicines
Paris, March
31, 2022. Sanofi
successfully priced yesterday, March 30, 2022, its offering of a
dual-tranche EUR 1.5 billion of notes (the “Notes”). It comprises
an inaugural issue of sustainability-linked bond for a nominal
amount of EUR 650 million of notes, tied to Sanofi’s commitment to
improve access to essential medicines in low- and
lower-middle-income countries via its global health nonprofit unit.
This transaction demonstrates Sanofi’s commitment to society, to
ensure access to healthcare for the world’s vulnerable people.
Jean-Baptiste de ChatillonChief
Financial Officer of Sanofi“A year after pioneering sustainable
finance with our sustainability-linked revolving credit facilities,
we further contribute to the development of the sustainable finance
market through the successful pricing of our first
sustainability-linked bond” said Jean-Baptiste de Chatillon, Chief
Financial Officer of Sanofi. “We continue to make progress in our
environmental, social and governance activities that are an
essential part of our strategy and embedded into our business.”
The Notes consist of two tranches:
- €850 million fixed rate notes, due
April 2025, bearing interest at an annual rate of 0.875%.
- €650 million fixed rate notes, due
April 2029, bearing interest at an annual rate of 1.250%. The
coupon amounts are linked to the achievement of a sustainability
performance target defined as the cumulative number of patients,
being at least 1.5 million patients, provided with essential
medicines by the global health unit, for the treatment of
non-communicable diseases in 40 of the world’s poorest countries,
between 2022 and 2026.
Sandrine Bouttier-StrefGlobal
Head of Corporate Social Responsibility of Sanofi“Linking the cost
of financing to the achievement of concrete targets in terms of
access to medicines confirms our determination to put social
responsibility at the center of our ambitions.”
Sanofi’s expanded social impact strategy aims to
build a healthier, more resilient world by ensuring access to
healthcare for the world’s poorest people and bringing a much
needed focus to the development of treatment for childhood cancer.
Integrated into the company’s Play to Win business strategy,
Sanofi’s commitment to society will continue the fight against
infectious diseases such as sleeping sickness and poliomyelitis,
while accelerating its goals to reduce the environmental impact of
its products and its worldwide operations. Key to tackling the
global challenges that face society are its people, who each have a
role to play in building a diverse and inclusive workplace.
To become an issuer of sustainable finance
instruments, Sanofi has established a dedicated
Sustainability-Linked Bond Framework, designed as a living document
to enable future bond issues in a sustainability-linked format. The
Sustainability-Linked Bond Framework is aligned with ICMA’s
Sustainability-Linked Bond Principles (2020) and has received a
Second Party Opinion from ISS ESG.
The proceeds of the bond issue will be used for
general corporate purposes.
The transaction has been led by Morgan Stanley
and Natixis CIB as Global Coordinators & Sustainability-Linked
Structuring Advisors and, Barclays, MUFG and RBC Capital Markets,
all as Joint Active Bookrunners.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25 |
sandrine.guendoul@sanofi.comSally
Bain | + 1 617 834 6026
| sally.bain@sanofi.comVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.comArnaud
Delépine | + 33 6 73 69
36 93 | arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.com
DisclaimerThis communication
shall not constitute an offer to sell or the solicitation of an
offer to buy nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. The Notes have
not been and will not be registered under the U.S. Securities Act
of 1933, as amended (the “Securities Act”) and may not be sold in
the United States absent registration or an exemption from
registration under the Securities Act. This communication is only
addressed to and directed at persons in member states of the
European Economic Area ("EEA") who are qualified investors within
the meaning of Article 2(e) of Regulation (EU) 2017/1129, as
amended (the "Prospectus Regulation").MiFID II
professionals/ECPs-only – Manufacturer target market (MiFID II
product governance) is eligible counterparties and professional
clients only (all distribution channels). No EU PRIIPs key
information document (KID) has been prepared as the securities will
not be available to retail in the EEA.UK MiFIR
professionals/ECPs-only – Manufacturer target market (UK MiFIR
product governance) is eligible counterparties and professional
clients only (all distribution channels). No UK PRIIPs key
information document (KID) has been prepared as the securities will
not be available to retail in the UK.This communication may only be
communicated in France to qualified investors (investisseurs
qualifiés) as defined in, and in accordance with, Article 2(e) of
the Prospectus Regulation and Articles L.411 -1 and L.411-2 of the
French Code monétaire et financier.This communication does not
constitute an offer of the securities to the public in the United
Kingdom. This communication is being distributed to and is directed
only at (i) persons who are outside the United Kingdom, (ii)
persons who have professional experience in matters relating to
investments falling within Article 19(5) of the Financial Services
and Markets Act 2000 (Financial Promotion) Order 2005, as amended
(the "Order"), (iii) persons who are high net worth entities
falling within Article 49(2)(a) to (d) of the Order, or (iv) are
other persons to whom they may otherwise lawfully be communicated
(all such persons together being referred to as "Relevant
Persons"). Any investment activity to which this communication
relates will only be available to and will only be engaged with,
Relevant Persons. Any person who is not a Relevant Person should
not act or rely on this document or any of its contents.
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on us, our customers, suppliers, vendors, and other business
partners, and the financial condition of any one of them, as well
as on our employees and on the global economy as a whole. Any
material effect of COVID-19 on any of the foregoing could also
adversely impact us. This situation is changing rapidly and
additional impacts may arise of which we are not currently aware
and may exacerbate other previously identified risks. The risks and
uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2021. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements. Sanofi does not undertake to make any updates to
information or forward-looking statements above subject to its
obligations under applicable regulations, inlcudign Article 223-1
and thereafter of the Règlement général of the AMF.
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024